Health Care [ 5/12 ] | Biotechnology [ 28/74 ]
NASDAQ | Common Stock
BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases.
The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.
It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions.
BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 27, 26 | -0.58 Increased by +61.21% | -1.04 Increased by +44.03% |
| Mar 23, 26 | -0.32 Decreased by N/A% | -0.77 Increased by +58.40% |
| Nov 13, 25 | -0.23 Decreased by -210.30% | -0.54 Increased by +58.17% |
| Aug 14, 25 | -1.02 Decreased by -16.80 K% | -0.53 Decreased by -92.15% |
| May 27, 25 | -1.50 Decreased by -14.91 K% | -1.06 Decreased by -41.57% |
| Mar 26, 25 | 0.00 Increased by +100.00% | -0.03 Increased by +100.00% |
| Nov 25, 24 | -0.07 Decreased by -628.00% | -4.40 Increased by +98.35% |
| Aug 15, 24 | 0.01 Increased by +102.03% | -0.14 Increased by +104.36% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 26 | 477.00 K Increased by +87.06% | -2.58 M Decreased by -150.34% | Decreased by -541.09% Decreased by -126.91% |
| Dec 31, 25 | 195.21 K Decreased by -98.34% | -1.39 M Increased by +56.27% | Decreased by -713.92% Decreased by -2.53 K% |
| Sep 30, 25 | 427.00 K Decreased by -91.36% | -977.00 K Increased by +83.22% | Decreased by -228.81% Decreased by -94.26% |
| Jun 30, 25 | 304.00 K Decreased by -94.36% | -3.94 M Decreased by -914.05% | Decreased by -1.30 K% Decreased by -14.54 K% |
| Mar 31, 25 | 255.00 K Decreased by -96.28% | 5.13 M Increased by +836.64% | Increased by +2.01 K% Increased by +19.90 K% |
| Dec 31, 24 | 11.75 M Increased by +144.77% | -3.19 M Increased by +77.05% | Decreased by -27.13% Increased by +90.62% |
| Sep 30, 24 | 4.94 M Increased by +N/A% | -5.82 M Increased by +63.66% | Decreased by -117.78% Decreased by N/A% |
| Jun 30, 24 | 5.39 M Increased by +N/A% | 484.00 K Increased by +102.61% | Increased by +8.97% Decreased by N/A% |